LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.810-3.010 for the period, compared to the consensus estimate of 2.610. The company issued revenue guidance of $276.0 million-$284.0 million, compared to the consensus revenue estimate of $271.3 million. LeMaitre Vascular also updated its Q1 2026 guidance to 0.640-0.690 EPS.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Roth Mkm reaffirmed a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Barrington Research restated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Friday, February 20th. Finally, Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Price Performance

LMAT stock traded up $0.63 during mid-day trading on Wednesday, hitting $91.38. The stock had a trading volume of 198,904 shares, compared to its average volume of 145,199. The firm has a fifty day simple moving average of $85.86 and a 200 day simple moving average of $88.09. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $105.55. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $2.07 billion, a P/E ratio of 39.39, a P/E/G ratio of 2.03 and a beta of 0.72.

Institutional Trading of LeMaitre Vascular

Large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the second quarter worth about $47,000. Geneos Wealth Management Inc. boosted its stake in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares in the last quarter. Quarry LP boosted its stake in shares of LeMaitre Vascular by 267.2% in the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after purchasing an additional 529 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of LeMaitre Vascular during the 4th quarter valued at approximately $68,000. Finally, Kemnay Advisory Services Inc. bought a new position in LeMaitre Vascular in the 4th quarter valued at approximately $80,000. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.